{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:50:22Z","timestamp":1787313022950,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109980","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:16:25Z","timestamp":1778451385000},"page":"109980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical evaluation of the antibody fragment targeting fibronectin EDB in the theranostics of radioactive iodine-resistant thyroid cancer"],"prefix":"10.1016","volume":"178","author":[{"given":"Wenyi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2026.109980_bb0005","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109980_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12935-022-02484-3","article-title":"Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma","volume":"22","author":"Samimi","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109980_bb0015","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1089\/thy.2020.0290","article-title":"Identification of SPRY4 as a novel candidate susceptibility gene for familial nonmedullary thyroid cancer","volume":"31","author":"Marques","year":"2021","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.bioorg.2026.109980_bb0020","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1089\/thy.2024.0216","article-title":"FGFR alterations in thyroid carcinoma: a novel class of primary drivers with significant therapeutic implications and secondary molecular events potentially mediating resistance in thyroid malignancy","volume":"34","author":"Sabbagh","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.bioorg.2026.109980_bb0025","article-title":"Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bioorg.2026.109980_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101013","article-title":"Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance","volume":"72","author":"Shen","year":"2024","journal-title":"Drug. Resist. Updat"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109980_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","article-title":"Radioactive iodine-refractory differentiated thyroid Cancer and redifferentiation therapy","volume":"34","author":"Liu","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"10","key":"10.1016\/j.bioorg.2026.109980_bb0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2213-8587(14)70051-8","article-title":"Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets","volume":"2","author":"Spitzweg","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109980_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/CCO.0000000000000349","article-title":"Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer","volume":"29","author":"Ibrahim","year":"2017","journal-title":"Curr. Opin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109980_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/mco.2020.2197","article-title":"Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (review)","volume":"14","author":"Babu","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"10.1016\/j.bioorg.2026.109980_bb0055","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2217\/fon.15.68","article-title":"Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?","volume":"11","author":"Lorusso","year":"2015","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109980_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11523-015-0363-z","article-title":"Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma","volume":"10","author":"Blair","year":"2015","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2026.109980_bb0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jconrel.2024.02.018","article-title":"Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models","volume":"367","author":"Ansari","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2026.109980_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101176","article-title":"Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies","volume":"78","author":"Wu","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109980_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092279","article-title":"Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer","volume":"13","author":"Fukuda","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109980_bb0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fendo.2017.00312","article-title":"Updates on the Management of Advanced, metastatic, and radioiodine refractory differentiated thyroid Cancer","volume":"8","author":"Tumino","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109980_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cen.13508","article-title":"Clinical guidance for radioiodine refractory differentiated thyroid cancer","volume":"88","author":"Gild","year":"2018","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.bioorg.2026.109980_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.720723","article-title":"Novel therapeutics in radioactive iodine-resistant thyroid Cancer","volume":"12","author":"Fullmer","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bioorg.2026.109980_bb0095","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/281261","article-title":"Targeting the tumor microenvironment: focus on angiogenesis","volume":"2012","author":"Fan","year":"2012","journal-title":"J. Oncol"},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2026.109980_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","article-title":"Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization","volume":"74","author":"Fukumura","year":"2007","journal-title":"Microvasc. Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109980_bb0105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates Tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109980_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112355","article-title":"Collateral damage intended-cancer-associated fibroblasts and vasculature are potential targets in cancer therapy","volume":"18","author":"Cavaco","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109980_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133253","article-title":"New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis","volume":"13","author":"Larionova","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.bioorg.2026.109980_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells11182863","article-title":"CAR-T-cell therapy for solid tumors positive for fibronectin extra domain B","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.bioorg.2026.109980_bb0125","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.109980_bb0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7150\/thno.44948","article-title":"Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma","volume":"11","author":"Saw","year":"2021","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109980_bb0135","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00259-023-06147-x","article-title":"EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer","volume":"50","author":"Li","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bioorg.2026.109980_bb0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/978-1-61779-974-7_31","article-title":"Fc engineering: serum half-life modulation through FcRn binding","volume":"907","author":"Olafsen","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109980_bb0145","first-page":"549","article-title":"(89)Zr-labeled anti-PD-L1 antibody fragment for evaluating in vivo PD-L1 levels in melanoma mouse model","volume":"35","author":"Bridgwater","year":"2020","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bioorg.2026.109980_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108969","article-title":"New prospects for (89)Zr-immuno-PET in brain applications - alpha-synucleinopathies","volume":"140-141","author":"Wuensche","year":"2025","journal-title":"Nucl. Med. Biol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109980_bb0155","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","article-title":"(89)Zr-Immuno-positron emission tomography in oncology: state-of-the-art (89)Zr radiochemistry","volume":"28","author":"Heskamp","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109980_bb0160","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11307-025-02053-w","article-title":"Peptide receptor radionuclide therapy with Lu-177-DOTATATE and monitoring with somatostatin receptor PET\/CT in patients with advanced differentiated thyroid carcinoma","volume":"27","author":"Kunte","year":"2025","journal-title":"Mol. Imaging Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109980_bb0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/1535-7163.MCT-24-0524","article-title":"Dual-nuclide biodistribution and therapeutic evaluation of a novel antibody-based radiopharmaceutical in anaplastic thyroid Cancer xenografts","volume":"24","author":"Lundgren Mortensen","year":"2025","journal-title":"Mol. Cancer Ther."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600516X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600516X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:47:34Z","timestamp":1779698854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600516X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S004520682600516X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109980","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of the antibody fragment targeting fibronectin EDB in the theranostics of radioactive iodine-resistant thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109980"}}